You are here

Home » Content

Flow Sitometri ile DNA İçerik ve Proliferasyon Aktivitesi Ölçümlerinin Prognostik Faktör Olarak Onkoloji Alanında Uygulanması

The application of DNA content and proliferation activity measurements with lion cytometry as prognostic factor in oncology field

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 1996

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Flow Cytometry (FC) is a technique that gives permission to measure several cellular features in a short time. FC has diagnostic and prognostic importance in oncology field. The measurement DNA content and proliferation activity is very easy with FC. In general aneuploid cell populations as well as diploid cell populations with a high proliferative component <S+ G2M) correlate with a more adverse prognosis in a number of malignancies. In this study the relationship between DNA content proliferation activity and prognosis on different cancer types are reviewed.
Bookmark/Search this post with
Abstract (Original Language): 
Flow Sitometri bir çok hücresel özelliği, kısa bir zamanda, objektif olarak ölçmeye izin veren bir tekniktir. Onkoloji alanında Flow Sitometri diagnostik ve prognostik öneme sahiptir. Flow Sitometri ile DNA içerik ve proliferasyon aktivitesi ölçümleri yapmak oldukça kolaydır. Genel olarak anöploid hücre popülasyonları veya yüksek proliferasyon komponentli (S-+G2M) diploid hücre popülasyonları malign olguların çoğunda kötü prognozla korelasyon göstermektedir. Bu çalışmada değişik kanser tiplerinde DNA içeriği ve proliferasyon aktiviteleri ve prognoz arasındaki ilişki yeniden gözden geçirilmiştir.
FULL TEXT (PDF): 
PDF icon arastirmax-flow-sitometri-ile-dna-icerik-proliferasyon-aktivitesi-olcumlerinin-prognostik-faktor-olarak-onkoloji-alaninda-uygulanmasi.pdf
  • 1
52-56
  • Turkish

REFERENCES

References: 

1. Andrzej M. Perspectives.In: Viehl P, editor. Guides to Clinical Aspiration Biopsy, Flow Cytometry. Igaku-Shoin, New York. 1991.
2. Yang OH, Louise H. Oncology applications of flow cytometry. Clin Lab Soi 1992:5:25-7.
3. Vindelov LL, Chirstensen IT. A review of techniques and results obtained in the laboratory by integrated system of methods designed for routine clinical flow cytometric DNA analysis. Cytometry 1990: 11: 753-70
4. Hedley DW, Friedlander ML, Taylor IW. Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance. Cytometry 1985;6:327-33.
5. McLemore DD, El-Naggar AK, Stephens LC, Jardine JH. Modified methodology to improve flow cytometric DNA histograms from paraffin- embedded material. Stain Technology 1990;65:279-91.
6. Hiddeman W, Schumann J, Andreef M, Barlogıe B, Herman JC, Leif RC, et al. Convention on nomenclature for DNA cytometry. Cytometry 1984;5:445-6
7. El-Naggar AK. Clinical relevance of the flow cytometric analysis in cancer. The Cancer Journal 1992;5: 321-7
8. Koss LG, Czerniak B, Herz F, Werstto RP. Flow Cytometric measurements of DNA and other cell components in human tumors. Human Pathology 1989; 20: 528-43.
9. Merkel DE, Dressier LG, McGuire WL. Flow Cytometry, cellular DNA content, and prognosis in human malignancy. J Clin Oncol 1987;5:1690-703.
10. Mellin W. Cytophotometry in tumor pathology. Path Res Pract 1990; 186: 37-62.
11. Frankfurt OS, Greco WR, Slocum HK, Arbuck SG, Gamarra M. Pavelic ZP. Rustum YM. Proliferative characteristics of primary and metastatic human solid tumors by DNA Flow Cytometry. Cytometry 1984; 5:629-35.
12. Seckinger D, Sugarbaker E, Franfurt O. DNA content in human cancer. Arch Pathol Lab Med 1989;113:619-26.
13. Williams NN, Daly JM. Flow cytometry and prognostic implications in patients with solid tumors. Surgery; Gynecology and Obstetrics 1990; 171:257-66.
14. Dressier Lg, Bartow SA. DNA Flow Cytometry in solid tumors: Practical aspects and clinical applications. Seminars in Diagnostic Pathology. 1989;6:55-82.
15. Van Dam PA, Watson JV, Lowe DG, Shepherd JH. Flow Cytometric DNA analysis in gynecological pathology. Int J Gynecol Cancer. 1992;2:57-65.
16. Kallioniemi OP, Mattila J, Punnonen R, Koivula T. DNA poidy level and cell cycle distribution in ovarian cancer: Relation to histopathological feature of the tumor. Int J Gynecol Pathol. 1988; 7:1-11.
17. Wagenius G, Bergström R, Strang P, Gerdes U, Rogo K, Tribukait B, Stendahl V.Prognostic significance of flow cytometric and clinical variables in endometrial adenocarcinoma stages I and II. Anticancer Research. 1992;12: 725-32.
Journal of Turgut Özal Medical Center 3(1): 1996
55
DNA flow sitometri ve onkoloji
A. Aydın
18 Coon JS Landay AL, Weinstein RS Biology of disease, advances in flow cytometry for diagnostic pathology. Laboratory investigation. 1987:57:453-73
19. Merkel DE, McGuire WL. Ploidy, proliferative activity and prognosis Cancer 1990;65:1194-205.
20 Ryan DH, Follan MA, Horan PK. Flow cytometry in the clinical laboratory. Clinica Chimica Acta 1988;171 ;125-74.
21 Sasaki K. Murakami T. Clinical application of flow cytometry for DNA analysis of solid tumors. Acta Pathol Jpn 1992:42:1-14.
22. Mangili F, Sassi I. Patetta M, Marelli G. Marabini R, Cantaboni A. Flow Cytometric diagnosis of partical mole. Path Res Parct 1992;188:425-27.
23. El-Naggar AK, Batsakis JG Teague K, Giacco G, Guinee VF, Swanson D. Acridine Orange Flow Cytometric analysis of renal cell carcinoma. Am J Pathol 1990; 137:275-80.
24. Melamed MR. Flow cytometry for dedection and evaluation of urinary bladder carcinoma. Semin in Surg Oncol. 1992;8:300-7.
25. Fnerson HF. Grade and Flow Cytometric analysis of ploidy for infiltrating ductal carcinomas. Hum Pathol. 1993;24:24-29.
26. Lipponen P, Papinaho S, Eskelinen M, et al. DNA ploidy, S phase fraction and mitotic indices as prognostic predictors of female breast cancer. Anticancer Research 1992:12: 1533-38.
27. El-Naggar AK, RO JY, Mclemore D, Garnsy L. DNA content and proliferative activity of cystosarcoma phyllodes of Breast. Am J Clin Pathol 1990: 93; 480¬85.
28. Briffod M, Sypratos F, Tubiana-Hulin M, et al. Sequential cytopunctures during preoperative chemotherapy for primary breast carcimoma. Cancer 1989;63:631-37.
29 Remvikos Y. Beuzebac P, Zajdela A, et al. Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst. 1989; 81:1383-87.
30. Seymour L, Bezuoda WR, Meyer K. Response to second-line hormone treatment for advanced breast cancer. Cancer 1990;65:2570-724.
31. Heliö H, Karaharju E, Nordling S. Flow Cytometric determination of DNA content in malignant and benign bone tumors. Cytometry 1985;6:165-71.
32. Kreicbergs A, Silvfersward C, Tribukait B. Flow DNA analysis of primary bone tumors. Cancer 1984: 53;
129-36.
33. Mankin HJ, Connor JF, Schiller Al, et al. Grading of bone tumors by analysis of nuclear DNA content using flow Cytometry. The Journal of Bone and Joint Surgery 1985;67:404-13.
34. Robey-Cefferty SS, El-Naggar AK, Şahin AA, et al. Prognostic factors in esophageal squamous carcinoma. Am J Clin Pathol. 1991 ;95:844-49.
35. Tsushima K, Nagomey DM, Reiman HM, Correlation of DNA ploidy, histopathology, stage and clinical outcome in gastric carcinoma. Surgical Oncology 1992;1:17-25.
36. Umehara Y, Kimura T. Yoshida M, et al. Heterogeneity in early and advanced gastric carcinoma by flow cytometric DNA analysis. Journal of Surgical Oncology 1993:52:97-100
37. Shimamoto T, Haruma K, Sumii K, et ai. Flow Cytometric DNA analysis of gastric smooth muscle tumors. Cancer 1992;70:2031-4.
38. Tsuchiya A, Ando Y, Ishii Y, et al. Flow Cytometric DNA analysis in Japanese colorectal cancer, multivariate analysis. European Journal of Surgical Oncology. 1992;18:585-90.
39. Fitzgibbons PL, Turner RR, Appley AJ, et al. Flow Cytometric DNA and nuclear antigen content in astrocytic neoplasms. Am J Clin Pathol. 1988;89:640-4.
40. El-Naggar AK. Ordenez NG , Gainsey L, et al. Epitheloid pleural mesotheliomas and pulmonary adenocarcinomas. Hum Pathol 1991 ;22:972-8.
41. El-Naggar AK. DNA Flow Cytometric analysis in the Assessment of soft-tissue neoplasms. The Cancer Bull. 1993;45:24-28.
42. Merkel DE, Dressier LG, McGuire WL. Flow Cytometry, cellular DNA content and prognosis in human malignancy. Journal of Clinical Oncology. 1987; 5:1690-703.
43. Diamond LW, Nathwani BN, Rappaport H. Flow Cytometry in the diagnosis and classification of malignant lymphoma and leukemia.Cancer 1982;50:1122-35.
44. Braylan RC, Flow Cytometric DNA analysis in the diagnosis and prognosis of lymphoma. Am J Clin Pathol 1993;99:374-80.
45. Clark R, Peters S, HayT, et al. Prognostic importance of hypodiploid hemopoietic precursors in myelodysplastic syndromes. N Engl J Med 1986;314:1472-75.
46. Walle AJ, Niedemayer W. Aneuploidy as a marker of minimal residual disease in leukemia. Cancer Dedection and Prevention 1985;8:303-15.
47. Barlogie B, McLaughlin P, Alexanion R. Characterization of hematologic malignancies by flow cytometry. Anal and Quant Cytol and Histol. 1987;9:147-55.

Thank you for copying data from http://www.arastirmax.com